Sanofi Q3 revenue beats estimates on new launches; lifts outlook

Overview

• France pharma firm's Q3 revenue rose 14.3% at CER, beating analyst expectations

• Business EPS for Q3 rose 19.6% at CER

• Company upgraded FY 2026 guidance for sales and business EPS growth at CER

Outlook

• Sanofi raises 2026 guidance, sees sales up by low-teens percentage at CER

• Company expects 2026 business EPS to grow by a mid-teens percentage at CER

• Sanofi says it is taking steps to offset Dupixent’s future loss of exclusivity

Result Drivers

• NEW MEDICINES - Co said Q3 sales growth was driven by launches of ALTUVIIIO, Ayvakit, and Rezurock

• DUPIXENT GROWTH - Co said strong Dupixent sales contributed to Q3 results

• COST DISCIPLINE - Co attributed business EPS growth to cost discipline

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 12 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Sanofi SA is €93.00, about 22.1% above its October 29 closing price of €76.15

• The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 9 three months ago

Reuters Recommended Reads

• Oct 28 - Sanofi agrees to settle antitrust case in US over diabetes drug Lantus

• Oct 27 - Novartis books $2.2 billion hit from drug trial setbacks, but lifts guidance

• Oct 28 - GSK pipeline doubts, vaccine underperformance overshadow sales beat

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)